[go: up one dir, main page]

LU90138I2 - Etoposide phosphate et ses sels et dérivés pharmaceutiquement acceptables (etopophos) - Google Patents

Etoposide phosphate et ses sels et dérivés pharmaceutiquement acceptables (etopophos)

Info

Publication number
LU90138I2
LU90138I2 LU90138C LU90138C LU90138I2 LU 90138 I2 LU90138 I2 LU 90138I2 LU 90138 C LU90138 C LU 90138C LU 90138 C LU90138 C LU 90138C LU 90138 I2 LU90138 I2 LU 90138I2
Authority
LU
Luxembourg
Prior art keywords
etopophos
derivatives
pharmaceutically acceptable
acceptable salts
etoposide phosphate
Prior art date
Application number
LU90138C
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LU90138I2 publication Critical patent/LU90138I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Cable Accessories (AREA)
LU90138C 1987-08-04 1997-09-24 Etoposide phosphate et ses sels et dérivés pharmaceutiquement acceptables (etopophos) LU90138I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8149387A 1987-08-04 1987-08-04
US07/199,731 US4904768A (en) 1987-08-04 1988-05-27 Epipodophyllotoxin glucoside 4'-phosphate derivatives

Publications (1)

Publication Number Publication Date
LU90138I2 true LU90138I2 (fr) 1997-11-26

Family

ID=26765636

Family Applications (2)

Application Number Title Priority Date Filing Date
LU87290A LU87290A1 (fr) 1987-08-04 1988-07-22 Derives de 4'-phosphates de glucosides d'epipodophyllotoxine
LU90138C LU90138I2 (fr) 1987-08-04 1997-09-24 Etoposide phosphate et ses sels et dérivés pharmaceutiquement acceptables (etopophos)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU87290A LU87290A1 (fr) 1987-08-04 1988-07-22 Derives de 4'-phosphates de glucosides d'epipodophyllotoxine

Country Status (34)

Country Link
US (3) US4904768A (fr)
JP (1) JPH0699465B2 (fr)
KR (1) KR900006230B1 (fr)
CN (1) CN1027169C (fr)
AT (1) AT398974B (fr)
BE (1) BE1002982A4 (fr)
CA (1) CA1310637C (fr)
CH (1) CH676716A5 (fr)
CY (1) CY1625A (fr)
CZ (1) CZ286893B6 (fr)
DD (2) DD274423A5 (fr)
DE (1) DE3826562A1 (fr)
DK (2) DK169344B1 (fr)
ES (1) ES2010775A6 (fr)
FI (1) FI87790C (fr)
FR (1) FR2622193B1 (fr)
GB (1) GB2207674B (fr)
GR (1) GR1000490B (fr)
HK (1) HK6392A (fr)
HU (3) HU208147B (fr)
IE (1) IE61040B1 (fr)
IL (1) IL87290A (fr)
IT (1) IT1226825B (fr)
LU (2) LU87290A1 (fr)
MX (1) MX173843B (fr)
MY (1) MY104321A (fr)
NL (2) NL192683C (fr)
NO (4) NO170284C (fr)
NZ (1) NZ225615A (fr)
PT (1) PT88186B (fr)
SE (1) SE502214C2 (fr)
SG (1) SG101291G (fr)
SK (1) SK279325B6 (fr)
YU (3) YU143688A (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191071A (en) * 1987-08-21 1993-03-02 Novo Nordisk A/S Monoesters of glycosides and a process for enzymatic preparation thereof
US4965348A (en) * 1989-05-19 1990-10-23 Bristol-Myers Company Dimeric epipodophyllotoxin glucoside derivatives
US5036055A (en) * 1989-06-07 1991-07-30 Bristol-Myers Company Acylated derivatives of etoposide
US5066645A (en) * 1989-09-01 1991-11-19 Bristol-Myers Company Epipodophyllotoxin altroside derivatives
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5034380A (en) * 1989-11-20 1991-07-23 Bristol-Myers Squibb Company Alkoxymethylidene epipodophyllotoxin glucosides
US5081234A (en) * 1990-04-30 1992-01-14 Bristol-Myers Squibb Co. 4'-demethylepipodophyllotoxin glycosides
US4997931A (en) * 1990-06-11 1991-03-05 Bristol-Myers Squibb Company Epipodophyllotoxin glycosides
TW260671B (fr) * 1991-04-29 1995-10-21 Bristol Myers Squibb Co
IT1250692B (it) * 1991-07-23 1995-04-21 Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
US5648474A (en) * 1991-10-08 1997-07-15 Bristol-Myers Squibb Crystalline etoposide 4'-phosphate diethanolate
JPH07632B2 (ja) * 1991-12-23 1995-01-11 ブリストル−マイヤーズ スクイブ カンパニー エトポシド４’−ホスフェート二ナトリウム塩の安定な六水和物
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
JP3061476B2 (ja) * 1992-04-24 2000-07-10 日本化薬株式会社 エトポシド燐酸エステルの製造法
US5459248A (en) * 1993-11-04 1995-10-17 Bristol-Myers Squibb Company Process of preparing etoposide phosphate and etoposide
FR2725990B1 (fr) * 1994-10-21 1997-01-10 Pf Medicament Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
CA2223484A1 (fr) * 1995-06-07 1996-12-19 Thomas Jefferson University Agents antifongiques et leurs procedes d'identification et d'utlisation
CA2247620A1 (fr) 1996-04-01 1997-10-09 Epix Medical, Inc. Agents de contraste bioactives destines a l'imagerie
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
WO1999032499A1 (fr) * 1997-12-23 1999-07-01 Korea Research Institute Of Chemical Technology DERIVES D'ACETAL DE 4'-O-DEMETHYL-EPIPODOPHYLLOTOXIN-β-D-GLUCOSIDE
EP1229934B1 (fr) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US6624317B1 (en) 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
US6506739B1 (en) 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
CA2464311A1 (fr) * 2001-10-26 2003-05-01 Centre National De La Recherche Scientifique Derives d'etoposide, analogues et compositions pharmaceutiques contenant lesdits derives
EP2281578A3 (fr) 2002-07-15 2011-04-13 Board of Regents, The University of Texas System Anticorps et peptides de duramycine sélectionnés se fixant à des phospholipides et des aminophospholipides anioniques et leur utilisation dans le traitement d'infections virales et du cancer
CA2516056C (fr) * 2003-01-06 2012-05-29 Angiochem Inc. Aprotinine et analogues comme transporteurs traversant la barriere hemato-encephalique
CN100334090C (zh) * 2005-02-02 2007-08-29 南京医科大学 吡啶类鬼臼毒素化合物及其制备方法和在制备杀虫剂中的应用
BRPI0520032A2 (pt) * 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP2471555A3 (fr) 2005-07-15 2012-10-17 Angiochem Inc. Utilisation de polypeptides d'aprotinine en tant que supports dans les conjugués pharmaceutiques
CN100410266C (zh) * 2006-01-11 2008-08-13 重庆华邦制药股份有限公司 鬼臼毒素磷酸酯衍生物的合成方法
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8263644B2 (en) * 2007-09-13 2012-09-11 Bristol-Myers Squibb Company Cytotoxic xanthone compounds
CN101918030B (zh) 2007-11-09 2015-10-14 派瑞格恩医药公司 抗vegf抗体的组合物和方法
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
TR201905480T4 (tr) * 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
WO2010043047A1 (fr) 2008-10-15 2010-04-22 Angiochem Inc. Conjugués d'agonistes de glp-1 et leurs utilisations
BRPI0920121A2 (pt) 2008-10-15 2019-09-24 Angiochem Inc conjugados de etoposida e doxorubicina para liberação de fármaco
WO2010063122A1 (fr) * 2008-12-05 2010-06-10 Angiochem Inc. Conjugués de neurotensine ou d'analogues de neurotensine et leurs applications
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
IN2012DN00248A (fr) 2009-07-02 2015-05-01 Angiochem Inc
CA2786294A1 (fr) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Composes de pyrido[3,2-d]pyrimidine inhibiteurs de pi3k delta et procedes d'utilisation
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
EP2771342B1 (fr) 2011-10-28 2016-05-18 Novartis AG Dérivés de purine et utilisation de ceux-ci dans le traitement d'une maladie
EP2788003A4 (fr) * 2011-12-09 2015-05-27 Demerx Inc Esters phosphoriques de noribogaïne
JP6381523B2 (ja) 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
CA2896133A1 (fr) 2012-12-20 2014-06-26 Demerx, Inc. Noribogaine substituee
PT3076969T (pt) 2013-12-06 2021-11-23 Novartis Ag Regime de dosagem de um inibidor de fosfatidilinositol 3- quinase seletivo para a isoforma alfa
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
WO2017077445A1 (fr) 2015-11-02 2017-05-11 Novartis Ag Schéma posologique pour un inhibiteur de la phosphatidylinositol 3-kinase
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
KR102378151B1 (ko) 2020-05-11 2022-03-24 주식회사 제이앤씨사이언스 베타-아포피크로포도필린의 신규한 유도체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1171314A (fr) * 1955-05-13 1959-01-23 Sandoz Ag Produits de condensation de glucosides avec des composés carbonyliques et leur préparation
NL6613143A (fr) * 1965-09-21 1967-03-22
CH464957A (de) * 1965-12-14 1968-11-15 Sandoz Ag Verfahren zur Herstellung eines neuen Glucosids
CH481094A (de) * 1966-12-13 1969-11-15 Sandoz Ag Verfahren zur Herstellung neuer Glucoside
CH514578A (de) * 1968-02-27 1971-10-31 Sandoz Ag Verfahren zur Herstellung von Glucosiden
CH543502A (de) * 1970-11-20 1973-10-31 Sandoz Ag Verfahren zur Herstellung neuer Glucoside
GB1395820A (en) * 1971-06-05 1975-05-29 Villax I Preparation of 21-inorganic esters of corticosteroids and salts thereof
CH589668A5 (en) * 1973-06-07 1977-07-15 Sandoz Ag Cytostatic (4')-demethyl substd. epipodophyllotoxin - prepd. from the corresp. glucopyranoside with (3)-thiophene-carboxaldehyde
FR2397425A1 (fr) * 1977-07-11 1979-02-09 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent
EP0111058B1 (fr) * 1982-11-26 1987-11-04 Nippon Kayaku Kabushiki Kaisha Procédé de préparation de 4'-déméthyl-épipodophyllotoxin-bêta-d-éthylidène-glucoside et dérivés acylés
US4567253A (en) * 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
JPS60246393A (ja) * 1984-05-22 1985-12-06 Nippon Kayaku Co Ltd エトポシドの新規製造法
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
IL77334A (en) * 1985-12-16 1991-04-15 Univ Bar Ilan Synthesis of 9-epipodophyllotoxin glucoside derivatives and some novel intermediates therefor
US4916217A (en) * 1987-01-08 1990-04-10 Bristol-Myers Company Phosphorus containing derivatives of epipodophyllotoxin
JPS63192793A (ja) * 1987-02-06 1988-08-10 Nippon Kayaku Co Ltd ４′−デメチル−エピポドフイロトキシン誘導体の新規エステル
US4874851A (en) * 1987-07-01 1989-10-17 Bristol-Meyers Company 3',4'-dinitrogen substituted epipodophyllotoxin glucoside derivatives

Also Published As

Publication number Publication date
GR880100512A (en) 1989-05-25
FI87790C (fi) 1993-02-25
GR1000490B (el) 1992-07-30
HUT47303A (en) 1989-02-28
IT1226825B (it) 1991-02-19
HU905862D0 (en) 1991-03-28
DK169344B1 (da) 1994-10-10
NO170284C (no) 1992-09-30
GB2207674B (en) 1991-09-11
IL87290A (en) 1993-01-31
CN1027169C (zh) 1994-12-28
NZ225615A (en) 1991-06-25
NL192683B (fr) 1997-08-01
HU208147B (en) 1993-08-30
JPH0699465B2 (ja) 1994-12-07
NO920277L (no) 1989-02-24
GB8818462D0 (en) 1988-09-07
NL970042I1 (nl) 1998-03-02
DE3826562A1 (de) 1989-02-16
FI87790B (fi) 1992-11-13
ES2010775A6 (es) 1989-12-01
MX173843B (es) 1994-03-30
KR900006230B1 (ko) 1990-08-27
AU2030688A (en) 1989-06-08
SK541288A3 (en) 1998-10-07
NO172440B (no) 1993-04-13
BE1002982A4 (fr) 1991-10-15
AT398974B (de) 1995-02-27
NO172440C (no) 1993-07-21
IL87290A0 (en) 1989-01-31
NO920665L (no) 1989-02-24
AU610619B2 (en) 1991-05-23
SE8802815D0 (sv) 1988-08-03
DK434088A (da) 1989-02-05
DK434088D0 (da) 1988-08-03
CA1310637C (fr) 1992-11-24
NL192683C (nl) 1997-12-02
IE61040B1 (en) 1994-09-07
US5041424A (en) 1991-08-20
SK279325B6 (sk) 1998-10-07
SE8802815L (sv) 1989-02-05
CY1625A (en) 1992-07-10
NO920665D0 (no) 1992-02-20
NL970042I2 (fr) 2005-06-01
MY104321A (en) 1994-03-31
US4904768A (en) 1990-02-27
IE882378L (en) 1989-02-04
FI883596A0 (fi) 1988-08-01
YU10390A (en) 1990-06-30
YU143688A (en) 1990-04-30
FR2622193B1 (fr) 1993-12-17
MX9202851A (es) 1992-06-30
HU211960A9 (en) 1996-01-29
ATA195588A (de) 1994-07-15
USRE35524E (en) 1997-06-03
IT8821535A0 (it) 1988-07-28
HU202547B (en) 1991-03-28
SE502214C2 (sv) 1995-09-18
DE3826562C2 (fr) 1993-04-08
DD299067A5 (de) 1992-03-26
CH676716A5 (fr) 1991-02-28
KR890003790A (ko) 1989-04-18
NO920277D0 (no) 1992-01-22
LU87290A1 (fr) 1990-02-07
FI883596A (fi) 1989-02-05
DD274423A5 (de) 1989-12-20
NO883299D0 (no) 1988-07-26
CZ541288A3 (cs) 1999-12-15
NO883299L (no) 1989-02-24
PT88186A (pt) 1989-06-30
YU10490A (en) 1990-06-30
FR2622193A1 (fr) 1989-04-28
CN1061225A (zh) 1992-05-20
PT88186B (pt) 1995-07-03
NO170284B (no) 1992-06-22
DK11992D0 (da) 1992-01-31
CZ286893B6 (cs) 2000-07-12
SG101291G (en) 1992-01-17
HK6392A (en) 1992-01-17
NL8801934A (nl) 1989-03-01
DK11992A (da) 1992-01-31
GB2207674A (en) 1989-02-08
NO1998002I1 (no) 1998-01-14
JPH01100188A (ja) 1989-04-18

Similar Documents

Publication Publication Date Title
LU90138I2 (fr) Etoposide phosphate et ses sels et dérivés pharmaceutiquement acceptables (etopophos)
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU88576I2 (fr) RISPERIDONE et ses sels pharmaceutiquement acceptables (Risperdal R)
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU90211I2 (fr) Miglitol et ses sels et dérivés pharmaceutiquement acceptables (diastabol)
LU88334I2 (fr) 9-(1,3-Dihydroxy-2-propoxyméthyl) guanine et ses sels pharmaceutiquement acceptables.
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU90244I2 (fr) Glimepiride et ses sels physiologiquement acceptables (amarylle r)
LU90944I2 (fr) Dérivés pipérazinyl-héterocycliques
FI96861C (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
FI905941A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten 2-asyyliaminotiatsolijohdannaisten valmistamiseksi
DK295288A (da) (1h-azol-1-ylmethyl)substituerede benzotriazolderivater
DK54488D0 (da) Adenosin-5'-carboxamid-derivater
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
MC2263A1 (fr) Aminobenzodiazepines et leurs sels pharmaceutiquement acceptables
LU88843I2 (fr) Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)
FI96601C (fi) Menetelmä terapeuttisesti aktiivisten tetratsolijohdannaisten valmistamiseksi
FI890028A0 (fi) Menetelmä 2-substituoitujen adenosiinijohdannaisten valmistamiseksi
LU88574I2 (fr) CEFEPIME et ses sels pharmaceutiquement acceptables (Maxipime R)
PT87854A (pt) Process for the preparation of thio-urea derivatives